In this episode, we sat down with Paul Andreola, from Smallcap Discoveries, whom is also a director of ImmunoPrecise Antibodies (TSXV: IPA). Paul joins us to discuss the company’s path of manufacturing therapeutic antibodies and the economic outlook of the pharmaceutical industry. Also shared is Smallcap Discoveries’ process of stock picking and evaluating the small cap arena.
A former broker and serial entrepreneur, Paul has been profiting in the smallcap space for over two decades. His relentless focus on growing, profitable smallcaps has uncovered some of Canada’s biggest winners in the last few years. Paul started Smallcap Discoveries to share his ideas and help retail investors reach their investing potential.
The author has no securities or affiliations related to any organization mentioned. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
